Lupin received approval from China’s National Medical Products Administration for Oseltamivir Phosphate Oral Suspension in partnership with Yabao Pharmaceuticals. The approval marks Lupin’s first entry into the Chinese pharmaceutical market. The 6 mg/mL oral suspension will be used for treatment and prevention of influenza A and B, particularly in paediatric patients.